Stock CVAC CUREVAC N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
2.88 USD -3.68% Intraday chart for CureVac N.V. +8.68% -31.59%
05-02 CUREVAC : A missed opportunity Alphavalue
04-26 UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CUREVAC : A missed opportunity
Alphavalue
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial
MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate
MT
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M
MT
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK
CI
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines
CI
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers
MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study
MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study
MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
CI
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK
MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates
MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15
DP
CureVac Patent Invalidated by German Court After BioNTech Nullity Action
MT
German Patent Court Grants BioNTech's Nullity Action Against CureVac
MT
CureVac Patent Invalidated by German Court After BioNTech Nullity Action
MT
German Patent Court Grants BioNTech's Nullity Action Against CureVac
MT
European Patent Office declares Moderna mRNA patent invalid
RE
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. News CureVac N.V.
  5. Highlights